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BACKGROUND
The efficacy and safety of prolonging prophylaxis for venous thromboembolism in 
medically ill patients beyond hospital discharge remain uncertain. We hypothe-
sized that extended prophylaxis with apixaban would be safe and more effective 
than short-term prophylaxis with enoxaparin.
METHODS
In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned 
acutely ill patients who had congestive heart failure or respiratory failure or other 
medical disorders and at least one additional risk factor for venous thromboembo-
lism and who were hospitalized with an expected stay of at least 3 days to receive 
apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days, or enoxa-
parin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days. 
The primary efficacy outcome was the 30-day composite of death related to venous 
thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or 
asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of sys-
tematic bilateral compression ultrasonography on day 30. The primary safety out-
come was bleeding. All efficacy and safety outcomes were independently adjudicated.
RESULTS
A total of 6528 subjects underwent randomization, 4495 of whom could be evaluated 
for the primary efficacy outcome — 2211 in the apixaban group and 2284 in the 
enoxaparin group. Among the patients who could be evaluated, 2.71% in the apixaban 
group (60 patients) and 3.06% in the enoxaparin group (70 patients) met the criteria 
for the primary efficacy outcome (relative risk with apixaban, 0.87; 95% confidence 
interval [CI], 0.62 to 1.23; P = 0.44). By day 30, major bleeding had occurred in 0.47% 
of the patients in the apixaban group (15 of 3184 patients) and in 0.19% of the 
patients in the enoxaparin group (6 of 3217 patients) (relative risk, 2.58; 95% CI, 
1.02 to 7.24; P = 0.04).
CONCLUSIONS
In medically ill patients, an extended course of thromboprophylaxis with apixaban 
was not superior to a shorter course with enoxaparin. Apixaban was associated with 
significantly more major bleeding events than was enoxaparin. (Funded by Bristol-
Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00457002.)
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V enous thromboembolism is a com-mon and potentially fatal complication in hospitalized surgical patients and acutely ill 
medical patients.1 The benefits of providing phar-
macologic thromboprophylaxis over the entire 
course of the hospital stay have been validated, with 
efficacy and safety shown in both populations.2-5
Among high-risk surgical patients, such as 
those undergoing total hip replacement, extended 
thromboprophylaxis in the period after hospital 
discharge has reduced the rate of both asymp-
tomatic and symptomatic venous thromboem-
bolism.6 On the basis of these findings, current 
practice guidelines recommend extended thrombo-
prophylaxis in such patients.7
One study (the Extended Prophylaxis for Venous 
Thromboembolism in Acutely Ill Medical Patients 
with Prolonged Immobilization trial [EXCLAIM; 
ClinicalTrials.gov number, NCT00077753])8 eval-
uated the potential advantage of extending phar-
macologic prophylaxis with enoxaparin beyond 
the period of hospitalization in acutely ill medical 
patients. Although the rates of venous thrombo-
embolism were lower with extended thrombopro-
phylaxis, this benefit was offset by a significant 
increase in major bleeding. In the MAGELLAN 
study (Venous Thromboembolic Event [VTE] Pro-
phylaxis in Medically Ill Patients, NCT00571649),9 
extended prophylaxis with rivaroxaban was com-
pared with short-term prophylaxis with enoxapa-
rin followed by placebo. This trial also showed 
lower rates of venous thromboembolism with 
extended thromboprophylaxis, but there were more 
major bleeding events with rivaroxaban than with 
enoxaparin.
Apixaban is an orally active direct inhibitor of 
activated factor X (factor Xa) with established 
efficacy and safety for the prevention of venous 
thromboembolism after elective hip or knee re-
placement10,11 and for the prevention of stroke in 
patients with atrial fibrillation.12,13 In the Apixa-
ban Dosing to Optimize Protection from Throm-
bosis (ADOPT) trial, we evaluated the potential 
of apixaban to prevent venous thromboembo-
lism in acutely ill medical patients during hospi-
talization and in the extended period after their 
discharge from the hospital.
Me thods
Study Oversight
The trial was designed and led by an executive 
committee that included academic investigators 
and by representatives of the sponsors (Bristol-
Myers Squibb and Pfizer). The study protocol, in-
cluding the statistical analysis plan, is available 
with the full text of this article at NEJM.org. The 
study was conducted according to the ethical 
principles stated in the Declaration of Helsinki. 
Approval was obtained from the appropriate eth-
ics committee at each site, and all patients pro-
vided written informed consent. All the authors 
participated in the design of the trial and the 
planning of the analyses. The first author wrote 
the first draft of the manuscript with input from 
all the coauthors and revised the subsequent 
drafts on the basis of input from the coauthors. 
All the authors vouch for the accuracy and com-
pleteness of the reported data and for the fidelity 
of the study to the protocol.
Patients
Male and female patients, 40 years of age or older, 
were considered for participation in the study if 
they were hospitalized for congestive heart failure, 
acute respiratory failure, infection (without septic 
shock), acute rheumatic disorder, or inflammatory 
bowel disease and had an expected hospital stay 
of at least 3 days. Except for patients with con-
gestive heart failure or respiratory failure, eligi-
ble patients had to have at least one of the follow-
ing additional risk factors: an age of 75 years or 
older, previous documented venous thromboem-
bolism or a history of venous thromboembolism 
for which they received anticoagulation for at least 
6 weeks, cancer, a body-mass index (the weight in 
kilograms divided by the square of the height in 
meters) of 30 or more, receipt of estrogenic hor-
mone therapy, or chronic heart failure or respira-
tory failure. In addition, all patients had to be 
moderately or severely restricted in their mobility. 
Moderately restricted mobility allowed for walk-
ing within the hospital room or to the bathroom. 
Severely restricted mobility was defined as being 
confined to bed or to a chair at the bedside.
Patients were excluded if they had confirmed 
venous thromboembolism; a disease requiring 
ongoing treatment with a parenteral or oral 
anticoagulant agent; active liver disease, ane-
mia or thrombocytopenia; severe renal disease 
(creatinine clearance of <30 ml per minute as 
estimated by the method of Cockcroft and Gault); 
a known or suspected allergy to enoxaparin; or 
prior heparin-induced thrombocytopenia or if they 
were taking two or more antiplatelet agents or 
aspirin at a dose higher than 165 mg per day. 
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Patients were also excluded if they had under-
gone a surgical procedure in the previous 30 days 
that might be associated with a risk of bleeding, 
had received anticoagulant prophylaxis for venous 
thromboembolism in the previous 14 days, were 
actively bleeding or were at high risk for bleeding; 
or had invasive procedures planned or scheduled 
during the treatment period. In addition, patients 
were excluded if they had one of the following 
abnormal laboratory findings: a hemoglobin level 
of less than 9 g per deciliter, a platelet count of 
less than 100,000 per cubic millimeter, an alanine 
or aspartate aminotransferase level more than 
twice the upper limit of the normal range, or direct 
or total bilirubin levels more than 1.5 times the 
upper limit of the normal range. Finally, women 
who might become pregnant, were pregnant, were 
breast-feeding, or were unwilling or unable to use 
an acceptable method of contraception were not 
eligible.
Study Design
This trial was an international, multicenter, ran-
domized, double-blind, controlled study. Patients 
were randomly assigned, in a 1:1 ratio, to receive 
apixaban, administered orally at a dose of 2.5 mg 
twice daily for 30 days, or enoxaparin, adminis-
tered subcutaneously at a dose of 40 mg once 
daily during their stay in the hospital, for a min-
imum of 6 days. Randomization was performed 
through a central telephone system with the use 
of a computer-generated randomization list. The 
maximum interval allowed between admission 
to the hospital and randomization was 72 hours. 
The day of randomization was defined as day 1 of 
the study. In-person follow-up visits were scheduled 
on study days 30±2 and 90±7, with telephone con-
tact at days 14 and 60. A systematic compression 
ultrasound examination was to be performed at 
the time of discharge (but no earlier than day 5 
and no later than day 14) and at day 30. All com-
pression ultrasound examinations were recorded 
for submission to an independent central adjudi-
cation committee whose members were unaware 
of the treatment assignments.
Treatments
The study medications were packaged in identi-
cal-appearing dispensing kits. Patients who were 
randomly assigned to apixaban received daily in-
jections of an enoxaparin placebo for a minimum 
of 6 days. After 6 days, the decision to discon-
tinue the parenteral study drug was made at the 
discretion of the investigators. Patients who were 
randomly assigned to enoxaparin received tablets 
containing an apixaban placebo for 30 days. Con-
comitant treatment with aspirin at doses above 
165 mg per day was prohibited.
Outcome Measures
The primary efficacy outcome was a composite 
during the 30-day treatment period of death re-
lated to venous thromboembolism (i.e., sudden 
death for which pulmonary embolism could not 
be excluded as a cause), fatal or nonfatal pulmo-
nary embolism, symptomatic deep-vein throm-
bosis, or asymptomatic proximal-leg deep-vein 
thrombosis as detected with the use of system-
atic bilateral compression ultrasonography. All 
components of the primary efficacy outcome 
were adjudicated by the independent central adju-
dication committee.
A key secondary efficacy outcome was the 
composite of total venous thromboembolism and 
death related to venous thromboembolism occur-
ring from the time of randomization to the time 
the blinded parenteral therapy was discontinued 
(the parenteral-treatment period). Additional sec-
ondary efficacy outcomes included symptomatic 
deep-vein thrombosis or nonfatal pulmonary 
embolism occurring during the 60-day follow-
up period, death from any cause occurring dur-
ing the 30-day treatment period, and death from 
any cause occurring during the entire 90-day 
study period (i.e., the treatment period plus the 
follow-up period).
The main safety outcomes included major 
bleeding, clinically relevant nonmajor bleeding, 
and all bleeding reported by investigators; myo-
cardial infarction; stroke; thrombocytopenia; and 
death from any cause. Each of these events was 
reviewed and adjudicated by the independent cen-
tral adjudication committee. Bleeding was cate-
gorized as major if it was fatal or overt and was 
accompanied by one or more of the following: 
a decrease in hemoglobin of 2 g or more per 
deciliter over a 24-hour period; transfusion of 
2 or more units of packed red cells; or intracra-
nial, intraspinal, intraocular, pericardial, or retro-
peritoneal bleeding, bleeding that occurred in an 
operated joint that required reoperation or inter-
vention, or intramuscular bleeding with the com-
partment syndrome. Clinically relevant nonmajor 
bleeding was defined as acute, clinically overt 
bleeding that did not meet the criteria for clas-
sification as a major bleeding event but did meet 
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at least one of the following criteria: epistaxis 
that required medical attention or persisted for 
5 minutes or more, gastrointestinal bleeding con-
taining frank blood or coffee-ground material that 
tested positive for blood, endoscopically confirmed 
bleeding, spontaneous hematuria or hematuria 
persisting for 24 hours or more after urinary-tract 
catheterization, unusual bruising, radiographically 
confirmed hematoma, or hemoptysis.
Statistical Analysis
We estimated that with a sample of 6524 patients 
randomly assigned in a 1:1 ratio to receive apixaban 
or enoxaparin, the study would have 90% power to 
show the superiority of apixaban with respect to 
the primary efficacy outcome, at a one-sided alpha 
level of 0.025, assuming a true event rate of 2.5% 
in the apixaban group and 4.0% in the enoxapa-
rin group. For the noninferiority test of the first 
secondary outcome (the composite of total venous 
thromboembolism and death related to venous 
thromboembolism during the parenteral-treatment 
period), the study would have 85% power to show 
the noninferiority of apixaban, at a one-sided alpha 
level of 0.025, assuming a true event rate of 1.6% 
in the apixaban group and 2.0% in the enoxapa-
rin group, with a noninferiority margin of 1.43 for 
the relative risk. These estimates were based on 
the use of the Mantel–Haenszel test for superiority 
and the test for noninferiority of Yanagawa, Tango, 
and Hiejima, stratified according to history or no 
history of venous thromboembolism and status 
with respect to cancer, and on the assumption 
that 10% of the compression ultrasound exami-
nations would not be able to be evaluated.
The primary efficacy data set consisted of all 
randomly assigned patients in whom compres-
sion ultrasonography was performed at any time 
up to the last scheduled visit during the treat-
ment period, with results that could be evaluated 
and were adjudicated; patients who had an event 
of venous thromboembolism, confirmed by adju-
dication, during the treatment period at any time 
from randomization to the last scheduled visit 
during the treatment period; or patients who died 
from a cause related to venous thromboembo-
lism during the treatment period. To control the 
overall type I error rate, a sequential test proce-
dure was planned to compare the effect of apixa-
ban with that of enoxaparin with respect to the 
primary efficacy outcome at day 30 and with 
respect to the first secondary outcome at the end 
of the parenteral-treatment period. 
The superiority of apixaban with respect to the 
primary outcome was first tested with the use of 
the Mantel–Haenszel test, stratified according to 
history or no history of venous thromboembolism 
and status with respect to cancer. If significant 
superiority were established for apixaban with 
respect to the primary outcome, a noninferiority 
test would then be performed on the first sec-
ondary outcome, with the use of the test for 
noninferiority of Yanagawa, Tango, and Hiejima, 
stratified according to history or no history of 
venous thromboembolism and status with respect 
to cancer.
The analysis of safety end points was performed 
on data from the treated population, which con-
sisted of all patients who received at least one 
dose of a study drug. Adjudicated major bleeding 
events were summarized according to onset dur-
ing the treatment period and onset during the 
follow-up period. An independent data and safe-
ty monitoring board reviewed the incidences of 
major bleeding and events of venous thrombo-
embolism on an ongoing basis, primarily to as-
sess safety. A formal interim efficacy analysis 
was performed after 50% of the planned patients 
had been enrolled.
R esult s
Study Patients
From June 2007 through February 2011, a total of 
6758 acutely ill medical patients were enrolled at 
302 centers in 35 countries, and 6528 subjects were 
randomly assigned to receive short-term prophylax-
is with enoxaparin or extended prophylaxis (30 days) 
with apixaban. In total, 4495 patients could be eval-
uated for the primary efficacy outcome at day 30. 
Figure 1 shows the number of patients who were 
enrolled, who underwent randomization, and who 
were included in the safety and efficacy analyses. 
The demographic characteristics of the study pop-
ulation, the primary diagnoses at enrollment, 
and additional risk factors are shown in Table 1. 
Among subjects who received at least one dose 
of the randomly assigned study medication, the 
mean (±SD) duration of exposure to apixaban was 
24.9±10.0 days, and the mean exposure to enoxa-
parin was 7.3±4.0 days.
Efficacy
The primary efficacy outcome, evaluated at day 30, 
occurred in 2.71% of the patients who were ran-
domly assigned to receive extended prophylaxis 
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with apixaban (60 of the 2211 patients in the pri-
mary efficacy data set) as compared with 3.06% 
of the patients who were assigned to receive short-
term prophylaxis with enoxaparin (70 of 2284 pa-
tients) (relative risk with apixaban, 0.87; 95% con-
fidence interval [CI], 0.62 to 1.23; P = 0.44). The key 
6528 Underwent randomization
6758 Patients were enrolled
230 Did not undergo
randomization
3255 Were assigned to receive
apixaban
3273 Were assigned to receive
enoxaparin
56 Did not receive
at least one dose
of study drug
71 Did not receive
at least one dose
of study drug
770 Were excluded from
day 10 efficacy 
analysis
767 Had missing or
nonanalyzable 
ultrasound
611 Had missing
ultrasound for
both legs
134 Had inadequate
ultrasound for
both legs
3 Had inadequate
assessment for
symptomatic VTE
785 Were excluded from
day 10 efficacy
analysis
784 Had missing or
nonanalyzable 
ultrasound
619 Had missing
ultrasound for
both legs
144 Had inadequate
ultrasound for
both legs
2 Had inadequate
assessment for
symptomatic VTE
3184 Were included
in safety analysis
2485 Were included in
day 10 efficacy analysis
2488 Were included in
day 10 efficacy analysis
3217 Were included
in safety analysis
1044 Were excluded from
day 30 efficacy
analysis
1043  Had missing or
nonanalyzable 
ultrasound
927 Had missing
ultrasound for
both legs
104 Had inadequate
ultrasound for
both legs
3 Had inadequate
assessment for
symptomatic VTE
989 Were excluded from
day 30 efficacy 
analysis
987 Had missing or
nonanalyzable 
ultrasound
874 Had missing
ultrasound for
both legs
102 Had inadequate
ultrasound for
both legs
7 Had inadequate
assessment for
symptomatic VTE
2211 Were included in
day 30 efficacy analysis
2284 Were included in
day 30 efficacy analysis
Figure 1. Enrollment, Randomization, and Follow-up.
Patients who were excluded from the efficacy analysis at day 10 could be included in the analysis at day 30 if they met the criteria at day 
30. Some patients who were excluded from the day 10 analysis or from the day 30 analysis had both inadequate assessment of symp-
tomatic venous thromboembolism and ultrasound examinations that were missing or could not be evaluated.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF DEBRECEN on April 11, 2012. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;23 nejm.org december 8, 20112172
Table 1. Baseline Characteristics of the Subjects.*
Variable Apixaban (N = 3255) Enoxaparin (N = 3273)
Demographic characteristics
Age — yr
Mean 66.8±12.0 66.7±12.0
Median 68.0 67.0
Range 40–101 40–98
Age distribution — no. (%)
<65 yr 1401 (43.0) 1411 (43.1)
 65 to <75 yr 890 (27.3) 884 (27.0)
≥75 yr 964 (29.6) 978 (29.9)
Sex — no. (%)
Male 1626 (50.0) 1577 (48.2)
Female 1629 (50.0) 1696 (51.8)
Race or ethnic group — no. (%)†
White 2474 (76.0) 2476 (75.6)
Black 292 (9.0) 304 (9.3)
American Indian or Alaskan Native 9 (0.3) 2 (0.1)
Asian 320 (9.8) 326 (10.0)
Other 145 (4.5) 149 (4.6)
Reason for hospitalization — no. (%)
Congestive heart failure 1270 (39.0) 1246 (38.1)
Acute respiratory failure 1208 (37.1) 1213 (37.1)
Infection, without septic shock 701 (21.5) 746 (22.8)
Acute rheumatic disorder 39 (1.2) 36 (1.1)
Inflammatory bowel disease 26 (0.8) 23 (0.7)
Other 6 (0.2) 5 (0.2)
Not reported 5 (0.2) 4 (0.1)
Additional risk factors — no. (%)
Previous venous thromboembolism 141 (4.3) 124 (3.8)
History of cancer‡ 312 (9.6) 320 (9.8)
Active cancer 113 (3.5) 98 (3.0)
Remote cancer 199 (6.1) 222 (6.8)
NYHA Class of chronic heart failure 1531 (47.0) 1537 (47.0)
I 60 (1.8) 47 (1.4)
II 228 (7.0) 240 (7.3)
III 854 (26.2) 833 (25.5)
IV 380 (11.7) 411 (12.6)
Not reported 9 (0.3) 6 (0.2)
Chronic respiratory failure 1683 (51.7) 1702 (52.0)
Body-mass index ≥30§ 1448 (44.5) 1451 (44.3)
Estrogenic hormone therapy 49 (1.5) 27 (0.8)
Mobility at randomization¶
Severely restricted 846 (26.0) 929 (28.4)
Moderately restricted 2388 (73.4) 2323 (71.0)
* Plus–minus values are means ±SD. There were no significant differences between the two treatment groups in any of 
the baseline characteristics. NYHA denotes New York Heart Association.
† Race or ethnic group was self-reported. The case-report forms for 0.4% of the patients in each group did not include in-
formation about race.
‡ Patients were considered to have active cancer if they had been receiving treatment for cancer within the previous year and 
were considered to have remote cancer if treatment for cancer ended more than a year before they were enrolled in the study.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ Moderately restricted mobility was defined as the ability to walk within the hospital room or to the bathroom. Severely 
restricted mobility was defined as being confined to the bed or to a chair at the bedside.
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secondary efficacy outcome of the composite of 
total venous thromboembolism (i.e., asymptomatic 
proximal deep-vein thrombosis, proximal or distal 
symptomatic deep-vein thrombosis, or pulmonary 
embolism) or death related to venous thrombo-
embolism evaluated at the end of the parenteral-
treatment period occurred in 1.73% of patients in 
the apixaban group (43 of 2485 patients) and in 
1.61% in the enoxaparin group (40 of 2488 patients) 
(relative risk, 1.06; 95% CI, 0.69 to 1.63). The rates 
of the primary and secondary efficacy outcomes 
are shown in Table 2. The results of the primary 
efficacy outcome were consistent across all pre-
specified subgroups.
The rate of symptomatic deep-vein thrombosis 
was lower among patients who received extended 
thromboprophylaxis with apixaban than among 
those who received enoxaparin (0.15% [5 of 3255 
patients] vs. 0.49% [16 of 3273 patients]), but this 
difference did not reach significance. The cumula-
tive rates of any symptomatic venous thromboem-
bolism, including death related to venous throm-
boembolism, are shown in Figure 2.
Safety Outcome
Table 3 shows the results of the bleeding out-
comes. Major bleeding events during the 30-day 
treatment period occurred in 0.47% of the patients 
in the apixaban group (15 of the 3184 patients 
who received at least one dose of apixaban) and in 
0.19% in the enoxaparin group (6 of the 3217 pa-
tients who received at least one dose of enoxaparin) 
(relative risk with apixaban, 2.58; 95% CI, 1.02 to 
7.24; P = 0.04). Major plus clinically relevant non-
major bleeding occurred in 2.67% of the patients 
who received apixaban (85 of 3184) and in 2.08% 
of those who received enoxaparin (67 of 3217) 
(relative risk, 1.28; 95% CI, 0.93 to 1.76; P = 0.12). 
The rates of total bleeding events in the apixaban 
and enoxaparin groups were 7.73% (246 of 3184) 
and 6.81% (219 of 3217), respectively (relative 
risk, 1.13; 95% CI, 0.95 to 1.34; P = 0.18). Figure 3 
shows the Kaplan–Meier curves for major and clin-
ically relevant nonmajor bleeding in both groups.
There was no significant difference in the rate 
of death between the apixaban group and the 
enoxaparin group (4.1% in each group [131 and 
133 patients, respectively]). The rates of adverse 
events, including myocardial infarction, stroke, 
and thrombocytopenia, did not differ significantly 
between the two groups during the treatment 
period or the follow-up period. The rates of ele-
vation of the alanine aminotransferase and total 
bilirubin levels to at least 3 times the upper 
limit of the normal range did not differ between 
the two groups.
Discussion
The primary efficacy outcome, a composite of 
venous thromboembolism and death related to 
venous thromboembolism, occurred in 2.71% 
of the patients randomly assigned to apixaban 
and in 3.06% of those assigned to enoxaparin 
(P = 0.44). However, there was an almost immediate 
increase in the risk of events when enoxaparin 
was stopped. After the parenteral-treatment period, 
the primary efficacy outcome occurred in 31 pa-
tients in the enoxaparin group but in only 18 pa-
tients receiving extended treatment with apixaban 
(relative risk with apixaban, 0.59%; 95% CI, 0.33 
to 1.05). When only symptomatic venous thrombo-
embolism and death related to venous thrombo-
embolism were included, extended treatment with 
apixaban reduced events from 18 to 8 (relative risk, 
0.44; 95% CI, 0.19 to 1.00). Therefore, even though 
our trial was negative, the strategy of extended 
prophylaxis with apixaban may have promise.
The ADOPT trial was underpowered. The 
13% reduction in the primary outcome favored 
apixaban, but the between-group difference was 
not significant, and thus no clinically directive 
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conclusion can be drawn. The results of this trial 
may not be applicable to typical populations of 
hospitalized medically ill patients because screen-
ing for venous thromboembolism with the use of 
compression ultrasonography is not performed 
routinely at the time of hospital discharge. Further-
more, the curves between apixaban and enoxa-
parin began to separate well after the final dose 
of enoxaparin was administered, suggesting that 
the study outcome might have been positive if we 
had extended the duration of apixaban therapy for 
more than 30 days.
The comparator in this trial was enoxaparin 
administered for 6 to 14 days. Although this is 
the licensed regimen for enoxaparin prophylaxis 
in medically ill patients, most patients who are 
hospitalized for a medical illness remain in the 
hospital for fewer than 5 days. It is standard prac-
tice to stop enoxaparin at the time of discharge, 
even in patients with persistent risk factors for 
venous thromboembolism. Thus, the design of 
this trial favored better efficacy in the enoxapa-
rin group than would be expected with ordinary 
clinical care because patients in the enoxaparin 
group received prophylaxis for a longer duration 
than usual.
The results of the ADOPT trial warrant com-
parison with two other contemporary trials evalu-
ating extended thromboprophylaxis in medically ill 
patients. In the EXCLAIM trial,8 5963 medically ill 
patients were given open-label enoxaparin (40 mg 
once daily) for an average of 10 days. As com-
pared with placebo, extended prophylaxis with 
enoxaparin reduced the rate of venous thrombo-
embolism from 4.0% to 2.5% but increased the 
rate of major bleeding from 0.3% to 0.8%.
The MAGELLAN trial compared extended pro-
phylaxis with oral rivaroxaban (10 mg once daily) 
with a 6-to-14-day course of subcutaneous enoxa-
parin (40 mg once daily) in 8101 medically ill pa-
tients.9 At day 35, the rate of the primary efficacy 
outcome was significantly lower with extended 
rivaroxaban than with enoxaparin (4.4% vs. 5.7%; 
hazard ratio with rivaroxaban, 0.77; 95% CI, 0.62 
to 0.96; P = 0.02). However, there was an increase 
in treatment-related major and clinically relevant 
nonmajor bleeding with rivaroxaban as compared 
with enoxaparin both during the period from 1 to 
10 days (2.8% and 1.2%, respectively) and during 
the period from 11 to 35 days (1.4% and 0.5%, 
respectively).
In the ADOPT trial, the rate of major bleed-
ing with apixaban was less than 0.5%. This rate 
is consistent with the safety of the regimen of 
2.5 mg of apixaban twice daily, which is the 
regimen that is licensed in Europe for thrombo-
prophylaxis after elective hip- or knee-replace-
ment surgery.
The strengths of the current trial include the 
large sample size; the randomized, double-blind, 
double-dummy design; the centralized adjudication 
of all suspected outcomes by a committee whose 
members were unaware of the treatment assign-
ments; and the enrollment of a broad population 
of medically ill patients. Some limitations are the 
inclusion of asymptomatic proximal deep-vein 
thrombosis as part of the primary efficacy out-
come and the fact that a follow-up ultrasound 
examination was performed in only 64% of the 
patients, which reduced the statistical power of 
the trial. Compression ultrasonography is not 
performed routinely in medical patients at the 
time of discharge from the hospital, and is per-
formed even more rarely at 1 month after dis-
charge. The low rate of asymptomatic proximal 
deep-vein thrombosis among patients who re-
ceived short-term prophylaxis validates this ap-
proach. In the ADOPT and MAGELLAN trials, the 
logistic complexity of performing compression 
ultrasonography in this frail patient population 
before discharge from the hospital and at 30 days 
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Figure 3. Kaplan–Meier Curves for the Composite of Major and Clinically 
Relevant Nonmajor Bleeding Events during the Treatment Period.
The inset shows the same data on an enlarged y axis.
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after discharge probably explains the suboptimal 
rates of follow-up examinations.
The ADOPT trial does not provide evidence to 
justify a policy of extended prophylaxis in a broad 
population of medically ill patients after hospital 
discharge. However, with event rates of venous 
thromboembolism at 30 days that range from 3% 
in the ADOPT trial to 5% and 6% in the EXCLAIM 
and MAGELLAN trials, respectively, it is clear that 
the risk of venous thromboembolism increases 
beyond the time of hospital discharge. More pre-
cise risk-stratification methods are needed to iden-
tify a narrower spectrum of medically ill patients 
who may benefit from extended prophylaxis.
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